An Evaluation of the Cost-Effectiveness of Rituximab in Combination with Chemotherapy for the First-Line Treatment of Follicular Non-Hodgkin's Lymphoma in the UK
Under an Elsevier user license
open archive
Keywords
advanced follicular lymphoma
cost-effectiveness
cost-utility
non-Hodgkin's lymphoma
rituximab
Cited by (0)
Copyright © 2010 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.